Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02864381 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT02864381 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 144 participants.
The verdict
NCT02864381, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Interventions
- DRUG Nivolumab
- DRUG Andecaliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2019-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02864381
The ClinicalTrials.gov registry entry for NCT02864381 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02864381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02864381 about?
NCT02864381 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma". The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.
What is the current status of trial NCT02864381?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2016-09-01. Estimated completion is 2019-08-23.
What interventions are being tested in trial NCT02864381?
The interventions under investigation include: Nivolumab (DRUG), Andecaliximab (DRUG).
Who is sponsoring clinical trial NCT02864381?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.